Document is current
Any future updates will be listed below
-
Authors
Bahat, Anat https://orcid.org/0009-0008-6045-6225
Itzhaki, Elad https://orcid.org/0009-0006-8478-1116
Weiss, Benjamin https://orcid.org/0000-0002-9084-9264
Tolmasov, Michael
Tsoory, Michael
Kuperman, Yael https://orcid.org/0000-0003-3830-1856
Brandis, Alexander
Shurrush, Khriesto A
Dikstein, Rivka https://orcid.org/0000-0002-6251-4723
-
Funding
Funding for this research was provided by:
Israel Innovation Authority Kamin
Hereditary Disease Foundation
Swiss Friends of the Weizmann Institute of Science
WIS Dr. Barry Shreman Institute for Medicinal Chemistry
- License Information
-
More Information
Article History
Received: 11 May 2023
Revised: 21 November 2023
Accepted: 7 December 2023
First Online: 19 February 2024
Disclosure and competing interests statement
: RD and AB declare a patent for the use of Spt5 inhibitors (U.S. Patent No. 20210379060). The rest of the authors declare no competing interests.
